FDA approves first human trial of Sinclair-backed epigenetic reprogramming therapy
Posted by former_codes in Longevity & Anti-Aging - 3 points, 4 comments.
The FDA gave Life Biosciences the green light to start a Phase 1 human trial of a gene therapy called ER-100, based on David Sinclair's epigenetic reprogramming theory of aging. The idea is to partially reprogram cells to rejuvenate them, and they are starting with optic neuropathies rather than whole-body aging.
I have mixed feelings about this. The partial reprogramming concept is actually fascinating from a pharmacology perspective, and the fact that FDA approved a human trial means the preclinical safety data was at least somewhat convincing. But Sinclair has a history of overpromising, and the jump from "we reprogrammed some mouse retinal cells" to "we are reversing aging in humans" is enormous. Starting with a specific eye condition is smart because it is a contained target, but I think people will read this as "immortality is coming" when really it is an early safety study in one indication.
Does anyone here think partial reprogramming will actually translate to broad longevity benefits in humans, or is this going to end up like most gene therapies where it works in one narrow application and nothing more? I am genuinely curious what the timeline looks like for something like this to reach anything beyond niche use.
Comments
- student748: For what it is worth i think starting with the optic neuropathy angle is the smartest thing they could do. Contained tissue, measurable endpoints, less risk of systemic weirdness. Thats just good trial design regardless of what you think of sinclair himself. The bit that gets me is whether partial reprogramming in vivo actually stays "partial" once you switch on those Yamanaka factors. You see the mouse data and its impressive but the teratoma risk is real if you overshoot. Curious if anyone he
- tired_lifter: That teratoma concern is exactly what keeps me from getting too excited about this one. From what I read, ER-100 uses an AAV vector with inducible expression, so there is some built-in control there, but whether that truly self-limits in human tissue or just slows things down... Nobody knows yet. The optic nerve being a contained site is smart, agreed, but "contained" only helps if the vector itself stays put.
- former_codes: The AAV vector spread point is actually the thing I worry about most. With AAV you get localized delivery in theory but biodistribution studies always show some leakage to liver and elsewhere. The inducible expression is a nice safety layer on paper but if the vector drifts to off-target tissue and the inducer is still circulating... That is a real question. Do you know if they said which inducer system they are using? I could not find that detail.
- former_codes: Yeah the optic neuropathy angle I completely agree with you, that is just solid trial design no matter what you think about Sinclair. The teratoma question is actually the thing that worries me most too. From what I read ER-100 uses an AAV vector with doxycycline-inducible Yamanaka factors, so theoretically you can stop expression by withdrawing doxycycline. But whether that is enough control once the reprogramming cascade is already running... I am not sure anyone really knows that yet in huma
Community discussion - research and educational context only. Not medical advice.